Taking On Vyvgart In Myasthenia Gravis

Argenx has aggressive market expansion plans for Vyvgart. It also has several late-stage challengers in what is becoming a dynamic market.

argenx N.V. might be justified in considering itself secure as market leader in the muscle weakening condition myasthenia gravis (MG), with its anti-neonatal Fc receptor (FcRn) antibody Vyvgart already a blockbuster in the condition.

Key Takeaways

Argenx is working to expand Vyvgart’s approved indications and settings, including in MG

But several products that are in the works appear to be flying under analysts’ radar, and with a flurry of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

18 Jun 2025

• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

UCB Follows Fellow European Pharmas With Major US Investment

13 Jun 2025

• By Kevin Grogan

The Belgian drugmaker is boosting its biologics capacity over the pond.

Sanofi Revels In More Positive Rilzabrutinib Data

12 Jun 2025

• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

12 Jun 2025

• By Andrew McConaghie

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.